期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 37, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s13046-018-0702-x
关键词
Next generation sequencing (NGS); Precision medicine; Genomic aberrations; Regulatory issues; Ethics; Patient advocacy; Bioinformatics; Cancer screening and prevention
类别
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC Nuvenia Fellowship) [19503, 14204, 19052]
- EU project ULTRAPLACAD [633937]
- Regina Elena Scientific Direction
The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive 'mid-size' Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology. Herein, we argue that besides its many practice-changing implications, this approval tears down the conceptual walls dividing system biology from clinical practice, diagnosis from research, prevention from therapy, cancer genetics from cancer genomics, and computational biology from empirical therapy assignment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据